Key Points {#FPar1}
==========

In this study, a more comprehensive picture of rosiglitazone metabolism was demonstrated.The work presented here will assist in the better management of rosiglitazone use in regard to polypharmacy and pharmacogenetics.

Introduction {#Sec1}
============

Rosiglitazone belongs to the synthetic thiazolidinedione class of drugs that improve insulin sensitivity in humans, and has been used as a potent glucose-lowering medicine in the treatment of type 2 diabetes \[[@CR1]--[@CR3]\]. Elimination of rosiglitazone in humans is mainly metabolic \[[@CR4]\] via *N*-demethylation and para-hydroxylation of the pyridine ring \[[@CR4]\] and has been reported to be the same in rats and dogs as in humans \[[@CR5], [@CR6]\]. All studies to date suggest that phase II metabolism conjugates the phase I metabolites by sulphation and glucuronidation, and that there is no direct conjugation of rosiglitazone \[[@CR4]\].

It has previously been reported that CYP2C8 is the major enzyme responsible for rosiglitazone metabolism in humans, with a minor contribution from CYP2C9 \[[@CR6]\]. However, all existing studies of rosiglitazone metabolism have been undertaken using the metabolite formation method, in which only the formation of *N*-desmethyl rosiglitazone and para-hydroxy rosiglitazone were considered \[[@CR6]\]. While formation of these two metabolites has been consistently reported in all 47 human liver microsome samples screened by the Baldwin group \[[@CR6]\], in vivo studies have demonstrated that *N*-desmethyl- and para-hydroxy-related metabolites of rosiglitazone (including their conjugate forms) account for only \~60% of rosiglitazone eliminated in urine and feces \[[@CR4]\]. This suggests that \~40% of rosiglitazone is eliminated in the form of metabolites that are not related to *N*-demethylation and para-hydroxylation pathways, and that other metabolic pathways and/or other cytochrome P450 enzymes also make a major contribution to rosiglitazone metabolism \[[@CR4]\]. Furthermore, in an in vivo study, ketoconazole, a potent inhibitor of CYP3A4 \[[@CR7]\], increased the plasma concentration of rosiglitazone by \~47% \[[@CR8]\]. Therefore, it appears that a complete picture of rosiglitazone metabolism is yet to be established.

The substrate depletion approach to investigating drug metabolism, unlike the metabolite formation method used in existing studies, provides the opportunity to investigate the total cytochrome P450-mediated metabolism of rosiglitazone without complete knowledge of the metabolites or access to the known metabolites. This approach is particularly valuable for obtaining a more complete picture of the kinetics of a substrate's metabolism, since the sum of the activity of all of the enzymes and all the metabolic pathways that contribute to the metabolism of the parent drug are considered in the evaluation of enzyme kinetics. Therefore, the aim of this study was to examine the in vitro metabolism of rosiglitazone and examine the impact of specific inhibitors on its metabolism in human liver microsomes using the substrate depletion method.

Materials and Methods {#Sec2}
=====================

Chemicals and Reagents {#Sec3}
----------------------

Rosiglitazone maleate was purchased from Selleck Chemicals LLC (TX, USA); acetonitrile was purchased from Scharlau Chemie S.A. La. Jota (Barcelona, Spain). Magnesium sulfate was purchased from Sigma (Steinheim, Germany). Montelukast was purchased from Sapphire Bioscience (Beaconsfield, NSW, Australia). DL-Isocitric acid, isocitric dehydrogenase, β-nicotinamide adenine dinucleotide phosphate sodium salt, furafylline, quinidine, 13-*cis* retinoic acid, diethyldithiocarbamate, and sulfaphenazole were purchased from Sigma-Aldrich (Castel Hill, NSW, Australia). Ketoconazole and troleandomycin were purchased from BIOTREND Chemikalien GmbH (Koln, Germany). Human liver microsomes were purchased from Celsis (In Vitro Technologies, Brussels, Belgium). Detailed information on these human liver microsomes is provided in Table [1](#Tab1){ref-type="table"}.Table 1General information of human liver microsomesSampleRaceGenderAgeCYBCaucasianFemale30JOXCaucasianFemale52PIMCaucasianFemale58YACCaucasianMale75ZILHispanicMale38

Milli-Q water was prepared using a Milli-Q Ultrapure Water System (Millipore, USA).

Microsomal Incubation {#Sec4}
---------------------

In this study, a substrate depletion method was used. The protein concentrations and incubation times for rosiglitazone metabolism in the microsomes were optimized to ensure that the metabolism of rosiglitazone at the incubation times and protein concentrations used in the final experiment followed first-order kinetics. Rosiglitazone metabolism in human liver microsomes (Table [1](#Tab1){ref-type="table"}) was performed in the incubation media using sodium phosphate buffer (100 mM, pH 7.4), with a final volume of 100 μL containing: 40 μg microsomal protein in 50 μL of buffer (equal to 0.4 mg/mL), 25 μL of the NADPH-generating system (including 7 mM NADP, 1.25 units isocitric acid dehydrogenase, 18 mM isocitric acid, and 20 mM magnesium chloride) \[[@CR9]\], and 25 μL rosiglitazone (at required concentrations). Incubations were performed at 37 °C in a shaking water bath for 0--25 min, with sampling times of 0, 5, 7.5, 10, 15, 20, and 25 min. The concentration of the remaining rosiglitazone in the supernatants was measured using the analytical method described in Sect. [2.4](#Sec6){ref-type="sec"}.

The kinetics of rosiglitazone metabolism were studied at the following rosiglitazone concentrations: 0.5, 2.5, 5, 10, 20, 40, 60, 80, 100, 200, 350, and 500 µM.

Inhibition Studies with Chemical Inhibitors {#Sec5}
-------------------------------------------

The assessment of the impact of specific P450 enzymes believed to be involved in the bio-transformation of rosiglitazone in humans was performed using two different sets of experiments.

One set of inhibition studies aimed to examine the impact of inhibition of P450 enzymes believed to be involved in the bio-transformation of rosiglitazone (CYP2C8 and CYP2C9) on metabolism kinetics. These experiments were performed across the full substrate concentration range between 0.5 and 500 µM using the same incubation conditions as described above. In this set of experiments, 40 μg microsomal protein in 25 μL of buffer (instead of in 50 μL of buffer) was used, thus allowing the addition of the inhibitor (25 μL), and the final volume of the incubation media remained the same at 100 μL. These inhibition studies were performed using 0.02 µM montelukast (CYP2C8) \[[@CR10]\] and 2.5 µM sulfaphenazole (CYP2C9) \[[@CR11]\].

The second set of inhibition studies aimed to screen the impact of specific P450 enzyme inhibitors other than CYP2C8 and CYP2C9 in the metabolism of rosiglitazone. These experiments were performed at a rosiglitazone concentration of 10 µM in triplicate, with the same incubation conditions as above. These inhibition studies were performed using 0.02 µM montelukast (CYP2C8), 2.5 and 10 µM sulfaphenazole (CYP2C9), 1 µM ketoconazole (CYP3A4) \[[@CR6]\], 10 µM furafylline (CYP1A2) \[[@CR6]\], 1 µM quinidine (CYP2D6) \[[@CR6]\], 142 µM 13-*cis* retinoic acid (CYP2C8) \[[@CR6]\], 40 µM troleandomycin (CYP3A4) \[[@CR6]\], and 40 µM diethyldithiocarbamate (CYP2E1) \[[@CR12]\], as well as both montelukast 0.02 µM (CYP2C8) and sulfaphenazole 2.5 µM (CYP2C9) in combination.

All inhibitions were performed at 37 °C in a shaking water bath for 0--25 min, with sampling times of 0, 5, 7.5, 10, 15, 20, and 25 min. In the inhibition study with furafylline, troleandomycin, and diethyldithiocarbamate, there was a further 10-min pre-incubation before adding rosiglitazone and initiation of sampling at the abovementioned time points \[[@CR6], [@CR12]\]. Appropriate controls for the inhibition studies with the final methanol concentrations above 0.1% \[[@CR13]\] were performed in individual human liver microsomes.

Quantification of Rosiglitazone in Incubated Microsomal Samples {#Sec6}
---------------------------------------------------------------

The concentrations of rosiglitazone in incubated samples were determined using the high-performance liquid chromatography (HPLC) assay described in detail previously \[[@CR14]\]. Briefly, the microsomal reaction was stopped by the addition of 300 μL of ice cold acetonitrile. The samples were then vortexed briefly before centrifugation at 16,200 rpm (12,200×*g*) for 20 min at 4 °C to separate the precipitated protein and supernatant. Then 20 μL of this supernatant was injected onto the HPLC system, and the concentration of the remaining rosiglitazone in the supernatants was measured using the HPLC assay. The detection of peaks was performed by using the fluorescence detector set at excitation and emission wavelengths 247 and 367 nm, respectively. The range of standard curve calibration was between 0.15 and 10 µM. Dilutions of one in 20 or one in 50 were applied after precipitation for samples with higher concentrations of rosiglitazone than those within the calibration curve range. The incubated samples with substrate concentrations of 20, 40, 60, 80, and 100 µM were diluted one in 20 with the mobile phase before injection into the HPLC. Samples with substrate concentrations of 200, 350, and 500 µM were diluted one in 50 with mobile phase before injection into the HPLC system.

Data Analysis and Determination of Enzyme Kinetics {#Sec7}
--------------------------------------------------

The depletion rate constant (*K* ~dep~) of rosiglitazone metabolism at each substrate concentration was calculated from the Ln concentration versus time profile, and then the concentration of rosiglitazone at time zero (*C* ~0~) was calculated. These were determined from the velocity of rosiglitazone metabolism in the microsomes over the full substrate range of 0.5--500 µM. To do this, the concentration of remaining rosiglitazone at each time point was transformed logarithmically (Ln concentration) and the slope (*K* ~dep~) and the intercept of the Ln concentration over time were estimated via linear regression of Ln concentration over time. *C* ~0~ was then calculated from the intercept as the exponent of the intercept. Then the initial reaction velocity at time zero (*v*) at each substrate concentration was calculated from *K* ~dep~ and *C* ~0~ using Equation (1). The reaction velocity at each substrate concentration was expressed as nmol·mg^−1^·min^−1^. Microsoft Excel (2007) was used for the calculations of *K* ~dep~, *C* ~0~, and *v*.

Equation 1: Calculating reaction velocity using *K* ~dep~ and *C* ~0~:$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$v = C_{0} \times K_{\text{dep}}$$\end{document}$$

To evaluate the enzyme kinetics of rosiglitazone metabolism, single enzyme kinetic models (Equations 2, 3, and 4) were fitted to each reaction velocity profile (velocity/substrate concentration).

Equation 2: Michaelis--Menten kinetics (MM, with two parameters):$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$v = \frac{{V_{\hbox{max} } \times S}}{{K_{\text{m}} + S}}$$\end{document}$$

Equation 3: Michaelis--Menten with substrate inhibition kinetics (MM,IS, with three parameters):$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$v = \frac{{V_{\hbox{max} } \times S}}{{K_{\text{m}} + S + K_{\text{i}} \times S^{2} }}$$\end{document}$$

Equation 4: Allosteric (cooperative) kinetics with three parameters:$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$v = \frac{{V_{\hbox{max} } \times S^{n} }}{{K_{\text{prim}}^{n} + S^{n} }}$$\end{document}$$where *V* ~max~ is the maximum velocity; *K* ~m~ is the substrate concentration at which the reaction velocity is 50% of *V* ~max~; *S* is substrate concentration; *K* ~i~ is the constant indicating the degree of substrate inhibition; *n* is equivalent to the allosteric coefficient for cooperative substrate binding; *K* ~prime~ (*K′*) is the substrate concentration at which the reaction velocity equals 50% of *V* ~max~ (equivalent to *K* ~m~ derived by the MM equation).

All fitting of the models was performed using Prism software (GraphPad Prism v5.01, GraphPad Software, Inc. CA, USA). The most appropriate enzyme kinetic model was selected according to the *F* test. Where the *F* test could not calculate the best fit because of equal parameters between two tested models, Akaike's information criterion (AIC) was used to determine the most appropriate enzyme kinetic model.

The inhibition data at a rosiglitazone concentration of 10 µM were expressed as the percentage of rosiglitazone depletion in the presence of the inhibitor compared with the control (with no inhibition). The mean of rosiglitazone metabolism in the presence of each inhibitor was compared with the control using the Student's *t* test. The correlation analyses between the total activity of rosiglitazone metabolism and the activity of individual P450 enzymes (provided by the manufacturer) were conducted using Pearson correlation analysis. All statistical analyses were performed using Prism software (GraphPad Prism v5.01, GraphPad Software, Inc. CA, USA).

Results {#Sec8}
=======

Kinetics of Rosiglitazone Metabolism {#Sec9}
------------------------------------

Rosiglitazone metabolism was NADPH dependent, and the enzyme kinetic model of Michaelis--Menten with substrate inhibition best described the kinetics of rosiglitazone metabolism in the majority of human liver microsome samples (Fig. [1](#Fig1){ref-type="fig"}). The kinetic parameters obtained from best model were as follows: *K* ~m~ between 17.1 and 29.8 (25 ± 5.57) µM, *V* ~max~ between 0.89 and 3.12 (1.64 ± 0.98) nmol·mg^−1^·min^−1^, and a *K* ~i~ between 4.25 and 234 (76 ± 91.9) µM. In only one sample (JOX) did the kinetics of rosiglitazone metabolism not converge in the MM,IS kinetic model, and it was best described with allosteric kinetics with a positive cooperativity (allosteric coefficient of *n* = 5.87), a *K′* of 912 µM, and a *V* ~max~ of 0.27 nmol·mg^−1^·min^−1^. The enzyme kinetic parameters of the metabolism of rosiglitazone in individual human liver microsomes are presented in Table [2](#Tab2){ref-type="table"} (see also Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Rosiglitazone metabolism velocity profile in human liver microsomes (with no inhibition). The *solid line* represents the curve of the best fit; the *inset* is the corresponding Eadie--Hofstee plot. *HLM* human liver microsomes Table 2Parameters of the best fitted models for enzyme kinetics with no inhibition and in the presence of CYP2C8 or CYP2C9 inhibitorsHLMInhibitionKinetic model*V* ~max~ (nmol·mg^−1^ ·min^−1^)*K* ~m~/*K′* (µM)*K* ~i~ (µM)*n*CYBNoMM,IS2.18 (0.03--4.32)^a^26.0 (0--58.9)20.4 (0--49.2)--CYP2C8MM,IS3.91 (0--14.7)82.8 (0--337)9.06 (0--38.4)--CYP2C9MM,IS1.26 (0--5.13)22.2 (0--109)14.6 (0--74.7)--JOXNoAllosteric0.27 (0.22--0.32)912 (0--10294)--5.87 (0--14.1)CYP2C8Allosteric0.24 (0.14--0.30)1664 (0--18309)--4.36 (0--10.3)CYP2C9Allosteric0.19 (0.06--0.1)205 (0--1742)--4.31 (0--10)PIMNoMM,IS0.90 (4.34--8.55)17.1 (7.21--26.9)234 (0--548)--CYP2C8MM,IS0.67 (0.32--1.01)12.3 (0.4--24)859 (0--7903)--CYP2C9MM,IS1.27 (0.4--2.13)26.7 (2.28--51.1)30.2 (0--63)--YACNoMM,IS0.89 (0.46--1.33)29.8 (9.82--49.7)54.6 (3.16--106)--CYP2C8MM,IS0.76 (0.15--1.38)24.5 (0--52.7)63.3 (0--170)--CYP2C9MM,IS1.08 (0--2.7)38.8 (0--118)26.8 (0--83)--ZILNoMM,IS3.12 (1.35--4.89)27.6 (5.39--49.8)67.3 (0--140)--CYP2C8MM,IS1.53 (0.73--2.32)13.4 (1.67--25.1)313 (0--1174)--CYP2C9MM,IS5.40 (0--15.4)55.1 (0--165)3.82 (0--11.7)--*HLM* human liver microsomes, *K* ~*i*~ the constant indicating the degree of substrate inhibition, *K* ~*m*~ the substrate concentration at which the reaction velocity is 50% of *V* ~max~, *K′* (*K* ~prime~) the substrate concentration at which the reaction velocity equals 50% of *V* ~max~ (equivalent to *K* ~m~ derived by the MM equation), *MM,IS* Michaelis--Menten with substrate inhibition kinetics, *n* equivalent to the Hill-coefficient for cooperative substrate binding, *V* ~*max*~ the maximum reaction velocity^a^The 95% confidence interval of the parameter

Impact of Inhibition on Rosiglitazone Metabolism Kinetics {#Sec10}
---------------------------------------------------------

The inhibition with montelukast or sulfaphenazole resulted in a slight decrease in the reaction velocity of rosiglitazone metabolism in all samples across the full substrate concentration range (between 0.5 and 500 µM) (Fig. [2](#Fig2){ref-type="fig"}). The kinetic parameters obtained for the best fitted enzyme kinetic model for the metabolism of rosiglitazone in individual human liver microsomes in the presence of the CYP2C8 or CYP2C9 inhibitors are provided in Table [2](#Tab2){ref-type="table"}. In the presence of montelukast, a *K* ~m~ between 12.3 and 82.8 (33 ± 33.5) µM, a *V* ~max~ between 0.66 and 3.91 (1.72 ± 1.5) nmol·mg^−1^·min^−1^, and a *K* ~i~ between 9.1 and 859 (311 ± 388) µM were observed. In the presence of sulfaphenazole, the *K*m was in the range of 22.2--55.1 (39.1 ± 15) µM, *V* ~max~ was in the range of 1.08--5.4 (2.2 ± 1.8) nmol·mg^−1^·min^−1^, and *K* ~i~ was between 3.8 and 30.2 (15.8 ± 12.4) µM. For sample JOX, in the presence of montelukast, the contributing enzyme showed a positive cooperativity (allosteric coefficient of *n* = 4.36), with the *K′* of 1667 µM and a *V* ~max~ of 0.24 nmol·mg^−1^·min^−1^. In the presence of sulfaphenazole, the kinetic parameters obtained from the allosteric kinetic model for sample JOX was allosteric coefficient of *n* = 4.31, a *V* ~max~ of 0.19 nmol·mg^−1^·min^−1^, and a *K′* of 205 µM (see Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Rosiglitazone metabolism velocity profile in human liver microsomes with CYP2C8 or CYP2C9 inhibition. The *solid line* represents the curve of the best fit. *HLM* human liver microsomes

Impact of Inhibition on Rosiglitazone Metabolism at 10 µM {#Sec11}
---------------------------------------------------------

The results of inhibition experiments at a single 10 µM rosiglitazone concentration are presented in Fig. [3](#Fig3){ref-type="fig"}. Among the inhibitors tested, only quinidine (CYP2D6, 14% inhibition) and furafylline (CYP1A2, 18% inhibition) did not significantly (*P* \> 0.05) decrease rosiglitazone metabolism compared with the rosiglitazone metabolism with no inhibition. In the presence of montelukast (CYP2C8, 49% inhibition), sulfaphenazole (CYP2C9, 30% inhibition at 2.5 µM and 42% inhibition at 10 µM), ketoconazole (CYP3A4, 52% inhibition), troleandomycin (CYP3A4, 41% inhibition), 13-*cis* retinoic acid (CYP2C8, 69% inhibition), and diethyldithiocarbamate (CYP2E1, 41% inhibition), and in the combination of both montelukast and sulfaphenazole (CYP2C8 and CYP2C9, 71% inhibition), there was a significant (*P* \< 0.05) decrease in rosiglitazone metabolism compared with the no inhibition condition (see Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Inhibition of rosiglitazone metabolism (10 µM) in human liver microsomes in the presence of CYP inhibitors. \*Significant difference (*P* \< 0.05) in comparison with control. *13-cis* 13-*cis* retinoic acid (CYP2C8) 142 µM, *Die* diethyldithiocarbamate (CYP2E1) 40 µM, *Fur* furafylline (CYP1A2) 10 µM, *Ket* ketoconazole (CYP3A4) 1 µM, *Mon* montelukast (CYP2C8) 0.02 µM, *Mon* *+* *Sul* montelukast (CYP2C8) 0.02 µM in combination with sulfaphenazole (CYP2C9) 2.5 µM, *Qui* quinidine (CYP2D6) 1 µM, *Sul* sulfaphenazole (CYP2C9) 2.5 µM or 10 µM, *Tro* troleandomycin (CYP3A4) 40 µM

Discussion {#Sec12}
==========

This study describes for the first time the evaluation of rosiglitazone metabolism in human liver microsomes using the substrate depletion method. Previous studies conducted using the product formation method reported that para-hydroxylation and *N*-demethylation are the main pathways of rosiglitazone metabolism in human liver microsomes, with the major contribution of CYP2C8 and a minor contribution of CYP2C9 \[[@CR6]\]. In this study, we took a very different approach (substrate depletion) to Baldwin's group (formation of metabolites) to assessing rosiglitazone metabolism and showed that further to the contribution of CYP2C8 andCYP2C9, CYP3A4 and CYP2E1 also contribute to the metabolism of rosiglitazone. The enzyme kinetics reported earlier using the product formation method for para-hydroxylation or *N*-demethylation of rosiglitazone in three human liver microsomes and two CYP2C8 Supersomes™ demonstrated ordinary Michaelis--Menten kinetics \[[@CR6]\]. However, in the present study, using the substrate depletion method (which considers the sum of the activity of all the contributing enzymes), rosiglitazone metabolism exhibited substrate inhibition kinetics in four samples and allosteric kinetics in one sample. This indicates that the kinetics of rosiglitazone metabolism in total (the sum of the total metabolism via all the contributing enzymes) is different to the kinetics of the para-hydroxylation and *N*-demethylation pathways alone.

The mean *V* ~max~ obtained using the substrate depletion method in the present study was only 0.59-fold of the mean value reported by Baldwin et al. \[[@CR6]\]. This was unexpected, since Baldwin and colleagues \[[@CR6]\] only measured the formation of para-hydroxylation and *N*-demethylation metabolites, accounting for only approximately 60% of total oxidative metabolism \[[@CR4]\], whereas the substrate depletion method used in the present study represents the sum of the total oxidative metabolism via all the contributing enzymes. One possibility for this apparent discrepancy is that the differences in the *V* ~max~ for rosiglitazone metabolism in our study and that of Baldwin and colleagues were due to inter-individual differences in the capacity to metabolize rosiglitazone. It has been demonstrated that the pharmacokinetics of rosiglitazone \[clearance (Cl) and terminal half-life (*t* ~½~)\] demonstrate inter-individual differences up to 2.6-fold \[[@CR4]\]. Furthermore, the range of rosiglitazone para-hydroxylation was from 1 to 38 nmol·mg^−1^·h^−1^ and its *N*-demethylation was from 0.8 to 31 nmol·mg^−1^·h^−1^ at the single substrate concentration of 10 µM in liver microsomes obtained from 47 individuals \[[@CR6]\], resulting in a combined activity in the order of 2--70 nmol·mg^−1^·h^−1^. The rosiglitazone metabolism in our study at the same concentration ranged from 11 to 47 nmol·mg^−1^·h^−1^ in the five samples we had access to, which is within the Baldwin's results range \[[@CR6]\]. This suggests that the lower *V* ~max~ in our study may have simply been due to the microsomes used in our experiments being derived from individuals with a lower capacity for rosiglitazone metabolism than the three samples used by Baldwin for the full kinetic experiments which determined *V* ~max~.

The contribution of the CYP2C8 enzyme to the metabolism of rosiglitazone in human liver microsomes was demonstrated in both sets of experiments in our study. In the presence of montelukast over a substrate range of 0.5--500 µM, the *K* ~dep~ and therefore the initial velocity of rosiglitazone metabolism decreased in all individual samples and there were changes in the kinetic parameters of rosiglitazone metabolism. The decrease in the initial velocity of rosiglitazone metabolism at a substrate concentration of 10 µM (the same concentration as in Baldwin's study \[[@CR6]\]) was also observed in all of the samples. Furthermore, in the other set of inhibition studies at a rosiglitazone concentration of 10 µM, the percentage of rosiglitazone depletion in the presence of montelukast or 13-*cis* retinoic acid was significantly lower than without inhibition. These findings are in agreement with previous studies where the contribution of CYP2C8 in the metabolism of rosiglitazone, using the drugs believed to be mainly specific for CYP2C8, fluvoxamine \[[@CR15]\] and trimethoprim \[[@CR16]\], and the CYP2C8 inducer, rifampin \[[@CR8], [@CR16]\], has been demonstrated. However, our study demonstrated that CYP2C9, CYP3A4, and CYP2E1 also contribute to the metabolism of rosiglitazone.

In humans, CYP2C8 is genetically polymorphic and the CYP2C8\*3 genotype confers altered metabolic activity of the CYP2C8 enzyme. The CYP2C8\*3 genotype is associated with decreased oxidative capacity in vitro for paclitaxel \[[@CR17]\]. In vivo, the CYP2C8\*3 genotype has been associated with increased metabolism of repaglinide and pioglitazone and also decreased metabolism of *R*-ibuprofen \[[@CR16], [@CR18], [@CR19]\]. For rosiglitazone, two clinical studies showed increased clearance of rosiglitazone in association with CYP2C8\*3 genotype \[[@CR18], [@CR20]\]; however, two other studies have shown no significant association between CYP2C8\*3 genotype and the pharmacokinetics of rosiglitazone \[[@CR14], [@CR21]\]. Therefore, this again suggests that CYP2C8 is not the only enzyme involved in the overall rosiglitazone metabolism.

The contribution of CYP2C9 to the metabolism of rosiglitazone was demonstrated in both sets of experiments. In the presence of sulfaphenazole over a substrate range of 0.5--500 µM, there were changes in the kinetic parameters of rosiglitazone metabolism. It has been reported that CYP2C9 has a minor contribution to the para-hydroxylation (\~15%) and *N*-demethylation (\~30%) of rosiglitazone in human liver microsomes \[[@CR6]\]. However, in our inhibition studies at a substrate concentration of 10 µM, the contribution of CYP2C9 in the metabolism of rosiglitazone was significant at the tested inhibitor concentrations, 30% inhibition at 2.5 µM and 42% inhibition at 10 µM. These findings suggest that while CYP2C9 might confer a minor contribution to para-hydroxylation and *N*-demethylation of rosiglitazone, it contributes almost the same as CYP2C8 to rosiglitazone metabolism overall.

The substrate depletion method does not provide information on metabolic pathways of a substrate; however, it can clearly demonstrate the contribution of CYP enzymes in the overall metabolism of the substrate. In this study, by using the substrate depletion method, we further demonstrated that other CYP enzymes, including CYP3A4 and CYP2E1, play a significant role in rosiglitazone metabolism. In an in vivo study in humans, ketoconazole increased the mean area under the plasma concentration--time curve (AUC) of rosiglitazone by 47% and also increased the peak plasma concentration of rosiglitazone by 17% \[[@CR8]\]; however, the authors concluded that the observed rosiglitazone inhibition was due to the inhibition of CYP2C8 or CYP2C9 by ketoconazole, despite the fact that ketoconazole is also a potent inhibitor of CYP3A4. It has been reported that ketoconazole (as a selective CYP3A4 inhibitor with the *K* ~i~ of 0.02--0.11 µM) can inhibit CYP2C8 activity with the *K* ~i~ of 2.5 µM \[[@CR7]\]. However, in our inhibition studies, the ketoconazole concentration was 1 µM (\<*K* ~i~ for CYP2C8 inhibition), and therefore, the observed inhibition appears to be due to selective CYP3A4, rather than CYP2C8, inhibition. Importantly, this is the same concentration used by Baldwin et al. \[[@CR6]\] in their work examining the formation of the *N*-desmethyl and para-hydroxy metabolites. They observed a 15% decrease in *N*-demethylation and about 3% decrease in para-hydroxylation of rosiglitazone, while we observed a 52% decrease in total rosiglitazone metabolism. Furthermore, using another selective inhibitor of CYP3A4, troleandomycin (40 µM), we demonstrated a 40% inhibition of rosiglitazone metabolism. The inhibition of CYP2C8 in the presence of 50 µM troleandomycin, which is slightly higher (1.2-fold) than that used in our work, has been reported to be less than 10% \[[@CR7]\]. Therefore, these combined results confirm the significant contribution of CYP3A4 in rosiglitazone metabolism, despite its relatively minor role in forming the *N*-desmethyl and para-hydroxy metabolites.

Our results also demonstrated a \~41% inhibition of rosiglitazone metabolism in the presence of a selective inhibitor of CYP2E1, diethyldithiocarbamate. Interestingly, Baldwin et al. in their work demonstrated a significant correlation between *N*-demethylation of rosiglitazone with lauric acid ω-1 hydroxylase (CYP2E1) activity in 47 human liver microsomes \[[@CR6]\]. However, they did not further investigate the contribution of CYP2E1 in rosiglitazone metabolism. Therefore, this is the first study that has demonstrated the significant contribution of CYP2E1 in the metabolism of rosiglitazone in human liver microsomes.

Since rosiglitazone has negligible renal clearance, it might be more susceptible to metabolic drug interactions. Databases for prescribing rosiglitazone, such as the Medical Information Management System (MIMS), indicate that CYP2C8 is the only responsible enzyme for rosiglitazone metabolism. In contrast, this study provides a more comprehensive picture of rosiglitazone metabolism and suggests that, in addition to CYP2C8, the contribution of CYP2C9, CYP3A4, and CYP2E1 to the metabolism of rosiglitazone is significant. The work presented here highlights the potential for drug--drug interactions to be underestimated when the assessment is based only on product formation metabolism studies, since these studies may not provide information on important metabolic pathways/enzymes that contribute to overall drug metabolism. Understanding the complete metabolism information of rosiglitazone will assist in improving the current therapeutic strategies and also in better managing its use in regard to polypharmacy and pharmacogenetics.
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